Noble Financial Raises Earnings Estimates for GeoVax Labs

GeoVax Labs Inc. (NASDAQ:GOVX) – Analysts at Noble Financial boosted their Q2 2026 EPS estimates for shares of GeoVax Labs in a research note issued on Tuesday, May 19th. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($2.88) for the quarter, up from their previous estimate of ($10.00). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.91) per share. Noble Financial also issued estimates for GeoVax Labs’ Q3 2026 earnings at ($3.28) EPS, Q4 2026 earnings at ($3.87) EPS and FY2026 earnings at ($12.65) EPS.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter.

GOVX has been the subject of several other research reports. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Stock Up 10.9%

NASDAQ:GOVX opened at $2.23 on Thursday. The company has a fifty day moving average of $1.43 and a 200-day moving average of $4.41. The firm has a market capitalization of $7.74 million, a P/E ratio of -0.12 and a beta of 3.36. GeoVax Labs has a twelve month low of $0.96 and a twelve month high of $34.75.

Institutional Trading of GeoVax Labs

Several hedge funds have recently modified their holdings of GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the 1st quarter valued at $27,000. HRT Financial LP bought a new stake in shares of GeoVax Labs in the 4th quarter valued at $31,000. Hudson Bay Capital Management LP acquired a new stake in GeoVax Labs in the 3rd quarter valued at $47,000. Renaissance Technologies LLC acquired a new stake in GeoVax Labs in the 4th quarter valued at $104,000. Finally, Armistice Capital LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at $253,000. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.